Clinical Evaluation of Lifitegrast Ophthalmic Solution 5.0% in Dry Eye Disease Using In Vivo Confocal Microscopy (NCT07560735)

🧪 Interventions in This Study

• Lifitegrast Ophthalmic Solution 5.0% (Xiidra) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• West Tennesse Eye Care dba Toyos Clinic — Nashville, Tennessee

📞 Contact the Study Coordinator

Phone: (615) 327-4015

Email: mtoyos@toyosclinic.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Dry Eye

• A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months. — Glendale, California
• A Single Center, Open-Label Study to Evaluate the Ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to Detect Tear Film Stability Utilizing Miebo® — Louisville, Kentucky
• DOMPE -MT Neurotrophic Keratitis — Nashville, Tennessee
• Penn SICCA Follow-up Study — Philadelphia, Pennsylvania
• Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment — Berkeley, California

Explore by condition: All Dry Eye clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.